Name: Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model (Video) | JoVE Journal
Uploaded: 2012-03-06T12:00:00.000+00:00
Duration: 8 min 2 s
Description: Learn how to establish an orthotopic glioblastoma model in mice for chemoradiation studies. This method enables researchers to implant tumor cells, monitor growth, and evaluate treatment efficacy using survival curves.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This research is supported by funding from the Intramural program of the NIH.

I. Cell Preparation
<ol>
	<li>The cells are grown to confluence in DMEM with 10% FBS about one 80% confluent 225 cm3 flask for every 5 mice to be implanted.</li>
	<li>Aspirate media off of the cells; wash with 10 ml of PBS without Calcium or Magnesium. Aspirate PBS off cells.</li>
	<li>Trypsinize cells with 3 ml of trypsin, wait 10-15 min, and neutralize the trypsin with 15 ml of media.</li>
	<li>Pipet all cells and media into a 50 ml conical. Two large flasks fit into one 50 ml conical.</li>
	<li>Spin cells at 1600 rpm for 7 min at 4 °C. Completely aspirate supernatant. Resuspend cells in 10 ml of cold PBS, and rinse cells by gently pipetting up and down. Make sure the cell pellet is mixed uniformly with the PBS. The suspension should be cloudy.</li>
	<li>At this time a cell count is done using a coulter counter. The cells are centrifuged again at 1600 rpm for 7 min at 4 °C.</li>
	<li>After the 2nd centrifugation of the cells, aspirate all PBS and resuspend in 1 ml of PBS.</li>
	<li>The cells are spun in the 1ml of PBS at 3000 rpm for 10 min at 4 °C. The PBS is aspirated, and PBS is added to adjust the final concentration to 1x106 per 5 μl for U87 cells, other cell lines may require a different number and concentration of cells for optimal tumor growth.</li>
	<li>After the final volume and concentration is obtained the cells are kept on ice in an eppendorf tube.</li>
</ol>
II. Xenograft
<ol class="ualpha">
	<li>Preparing the mouse
	<ol>
		<li>The mice are anesthetized using an injection mix of Ketamine/Xylazine/Saline. The mixture is 120 mg/kg of Ketamine, 16 mg/kg of Rompun and Saline. The mice are weighed individually and given 0.1 ml per 10 g based on their weight. The anesthetic is given with 26G needle attached to 1 ml syringe IP. It will take approximately 15 min for the mice to reach a sleeping phase for no pain response. You can check the pain response of the mice by pinching their footpad.</li>
		<li>After the mouse is fully anesthetized, eye ointment is administered to their eyes to prevent them from drying out.</li>
		<li>The mouse is placed on the bed of the stereotaxic with the front upper teeth in the notch on the mouth bar. The bed is then placed in the stereotaxic.</li>
		<li>The nose guard is placed over the mouse's nose to prevent movement of the head, and the ear bars are gently place in the ear canals of the mice. Be careful not to do either placement of the nose bar or ear bars too tight, as the skull may fracture and/or prevent the mouse from breathing.</li>
		<li>Make sure that the head of the mouse is level using the tick marks on the stereotaxic is helpful during this process.</li>
		<li>To prep the mouse, alcohol and providine iodine is applied liberally on the head of the mouse alternating for a total of 3 application of alcohol and 3 applications of iodine. One final application of an alcohol pad with 70% is applied to the head.</li>
	</ol>
	</li>
	<li>Surgical procedure
	<ol>
		<li>All instruments in the procedure should be sterilized either by autoclaving or soaking instruments in 70% ethanol before beginning the procedure.</li>
		<li>An incision is made on top of the skull behind the right eye diagonally back to the left posterior of the skull. The incision should be about 10 mm to 15 mm long.</li>
		<li>Using a Q-tip, slowly separate the incision to expose the skull and wipe away the membrane that is between the skull and the skin. Use a Q-tip to blot any blood and watch for excessive bleeding.</li>
		<li>Expose the top of the skull to visualize the bregma. Using the Hamilton syringe point, position it over the bregma. The correct position of the hole to be drilled in the skull is 2 mm right and 1 mm anterior of bregma (figure 2). A surgeon's felt-tipped marker, that is purchased sterile, is used to mark the location of the hole to be drilled. Please note that the hole is located close to the anterior suture line.</li>
		<li>Next, drill a small hole in the skull at the marked position using the point of a 22G needle in a pin vase or fed through an 18G needle.</li>
		<li>Load the 10 μl glass Hamilton syringe with 5 μl of cells. The Hamilton syringe is 10 μl with a blunt 30G to 33G fixed needle attached to it. Be sure to mix the cells before loading them, either by pipetting them or using a 1ml syringe with a 25G needle attached. After the Hamilton syringe is loaded, place it back in the arm to line it up with the hole in the skull.</li>
		<li>Lower the bunt end of the needle to the surface of the skull, once the needle is level with the skull; lower the needle until it is at the depth of 3 mm below the surface of the skull.</li>
		<li>After the needle is lowered, it shall remain there for 2 minutes to avoid any major trauma from the needle affecting the brain. Implanting the cells is at a rate of 1 μl per minute for a total of 6-8 minutes, be careful of any backflow. After the last of the cells have been implanted, leave the needle in place for another 2 minutes, to allow all the cells to settle in.</li>
		<li>Remove the needle from the brain, and clean the hole with a Q-tip. Proceed to clean the needle and syringe with 50% Actone, 100% EtOH, and PBS, 3x in each solution and in that order.</li>
		<li>The skin on the skull is ready to be sutured at this point. Using 5-0 PBS close the incision with about 3 stitches.</li>
		<li>Allow the mouse to wake up on a heat pad, and reapply eye ointment if needed. The mouse can be returned to the cage after it shows movement on its own (i.e. Lifting up the head or moving the shoulders).</li>
	</ol>
	</li>
</ol>
III. Treatment of the IC implant By Radiation and Drug
<ol class="ualpha">
	<li>Radiation treatment
	<ol>
		<li>Depending on the cell line, treatment of the mice can take place 5 to 7 days post-implant. Our department uses an orthovoltage radiotherapy unit for radiation treatment.</li>
		<li>Imaging such as BLI (Bioluminescence Imaging), MRI or CT can be used to visualize the tumor prior to randomization (figure 3A).</li>
		<li>The mice are anesthetized with the Ketamine/Xylazine/saline cocktail as before, and eye ointment is applied to their eyes.</li>
		<li>The mice are positioned in a custom made radiation jig that is configured like a pie wheel, in which the heads of the mice point towards the center. The bodies of the mice are shielded from the radiation with lead.</li>
		<li>Drug treatment can be given either before or radiation through different delivery routes, i.e. SQ, IP and IV.</li>
	</ol>
	</li>
</ol>
IV. Results
The mouse should wake up from the procedure within 45-60 minutes after anesthesia injection. If the mouse has difficultly waking up after the procedure and time has exceeded 1½ hr after the procedure, the mouse may not recover and euthanasia may be an effective alternative. If there is excessive bleeding or the skull becomes cracked at any point during the procedure euthanasia is advised. If all goes well and depending on the cell line, a tumor should start forming within 2-4 weeks after the procedure has take place. When using intracranial xenograft models, therapeutic efficacy is usually measured as survival post-implantation5. However, as this is an IC model signs and symptoms will occur prior to death. Some of the physical signs the mouse may exhibit are a hunched posture, loss of body weight, and inactivity. Some of the neurological signs may be seizures, head tilt, and loss of balance. Figure 3B shows an HE stain of a tumor at mortality. A Kaplan-Meier plot is used to evaluate the data (figure 4). The number of days of survival at 50% are calculated and compared to the control. If the combination group lived longer than the addition of the individual radiation and drug arms the combination is was successful.
<img alt="Stereotaxic surgery apparatus for precise brain targeting in neuroscience experiments." src="/files/ftp_upload/3397/3397fig1.jpg" data-altupdatedat="1761809329000" data-alt="Figure 1"> 
Figure 1. The Stoelting Stereotaxic equipment.
<img alt="Skull anatomy diagram with measurements indicating location of bregma, highlighting cranial structure." src="/files/ftp_upload/3397/3397fig2.jpg" data-altupdatedat="1761809329000" data-alt="Figure 2"> 
Figure 2. A diagram of the location of the drill hole in the mouse skull.
<img alt="Bioluminescence imaging, animal subject, day 10, intensity scale, research study analysis." src="/files/ftp_upload/3397/3397fig3A.jpg" data-altupdatedat="1761809329000" data-alt="Figure 3A"> 
Figure 3A. BLI imaging after GBM implantation.
<img alt="Histology slide, brain tissue cross-section, microscopy image, cellular structure analysis." src="/files/ftp_upload/3397/3397fig3B.jpg" data-altupdatedat="1761809329000" data-alt="Figure 3B"> 
Figure 3B. H and E of GBM tumor at mortality.
<img alt="IC implant survival curve with PARP inhibitor; line graph showing treatment effects over time." src="/files/ftp_upload/3397/3397fig4.jpg" data-altupdatedat="1761809329000" data-alt="Figure 4"> 
Figure 4. Results of U87 IC implants injected with PARP inhibitor 7 days post surgery.

<ol><li>Bleau, A. M., Holland, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Trapping+the+mouse+genome+to+hunt+human+alternations%5BTitle%5D)+AND+%22Proc.+Nat.+Acad.+Sci.+U.S.A%22%5BJournal%5D)">Trapping the mouse genome to hunt human alternations.</a> Proc. Nat. Acad. Sci. U.S.A. 104, 7737-7738 (2007).</li>
<li>McGrady, B. J., McCormick, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+murine+model+of+intracranial+invasion%3A+morphological+observations+on+central+nervous+system+invasion+by+melanoma+cells%5BTitle%5D)+AND+%22Clin.+Exp.+Metastasis%22%5BJournal%5D)">A murine model of intracranial invasion: morphological observations on central nervous system invasion by melanoma cells.</a> Clin. Exp. Metastasis. 10, 387-393 (1992).</li>
<li>Fei, X., Zhang, Q., Dong, J., Diao, y, Wang, Z., Li, R., Wu, Z., Wang, A., Lan, Q., Zhang, S., Huang, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+clinically+relevant+orthotopic+xenograft+mouse+model+of+metastatic+lung+cancer+and+glioblastoma+through+surgical+tumor+tissues+injection+with+trocar%5BTitle%5D)+AND+%22Journal+of+Experimental+%26+Clinical+Cancer+Research%22%5BJournal%5D)">Development of clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissues injection with trocar.</a> Journal of Experimental & Clinical Cancer Research. 29, 84-84 (2010).</li>
<li>Fujita, M., Zhu, X., Sasaki, K., Ueda, R., Low, K., Pollack, I., Okada, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inhibition+of+STAT3+Promotes+the+Efficacy+of+Adoptive+Transfer+Therapy+Using+Type-1+CTLs+by+Modulation+of+the+Immunological+Microenvironment+in+a+Murine+Intracranial+Glioma%5BTitle%5D)+AND+%22J.+Immunol%22%5BJournal%5D)">Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma.</a> J. Immunol. 180, 2089-2098 (2008).</li>
<li>Candolfi, M., Curtin, J. F., Nichols, W. S., Muhammad, A. K. M. . G., King, G., Pluhar, G. D., McNiel, G. E., Ohlfest, E. A., Freese, J. R., Moore, P. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Intracranial+glioblastoma+models+in+preclinical+neuro-oncology%3A+neuropathlogical+characterization+and+tumor+progression%5BTitle%5D)+AND+%22J.+Neurooncol%22%5BJournal%5D)">Intracranial glioblastoma models in preclinical neuro-oncology: neuropathlogical characterization and tumor progression.</a> J. Neurooncol. 85, 133-148 (2007).</li>
<li>Kaye, A., Morstyn, G., Gardner, I., Pyke, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+a+xenograft+glioma+model+in+mouse+brain%5BTitle%5D)+AND+%22Cancer+Research%22%5BJournal%5D)">Development of a xenograft glioma model in mouse brain.</a> Cancer Research. 46, 1367-1373 (1986).</li>
<li>Zhao, Y., Xiao, A., diPierro, C., Carpenter, J., Abdel-Fattah, R., Redpath, G., Lopez, M., Hussaini, I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+Extensive+Invasive+Intracranial+Human+Glioblastoma+Xenograft+Model%5BTitle%5D)+AND+%22American+Journal+of+Pathology%22%5BJournal%5D)">An Extensive Invasive Intracranial Human Glioblastoma Xenograft Model.</a> American Journal of Pathology. 176, 3032-3049 (2010).</li>
<li>Learn, C., Grossi, P., Schmittling, R., Xie, W., Mitchell, D., Karikari, I., Wei, Z., Dressman, H., Sampson, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genetic+Analysis+of+Intracranial+Tumors+in+a+Murine+Model+of+Glioma+Demonstrate+a+Shift+in+Gene+Expression+in+Response+to+Host+Immunity%5BTitle%5D)+AND+%22J.+Neuroimmunol%22%5BJournal%5D)">Genetic Analysis of Intracranial Tumors in a Murine Model of Glioma Demonstrate a Shift in Gene Expression in Response to Host Immunity.</a> J. Neuroimmunol. 182, 63-72 (2007).</li>
<li>Martens, T., Laabs, Y., Günther, H., Kemming, D., Zhu, Z., Witte, L., Hagel, C., Westphal, M., Lamszus, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inhibition+of+Glioblastoma+Growth+in+a+Highly+Invasive+Nude+Mouse+Model+Can+Be+Achieved+by+Targeting+Epidermal+Growth+Factor+Receptor+but+not+Vascular+Endothelial+Growth+Factor+Receptor-2%5BTitle%5D)+AND+%22Clin.+Cancer+Res%22%5BJournal%5D)">Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2.</a> Clin. Cancer Res. 14, 5447-5458 (2008).</li>
<li>Purow, B., Schiff, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Advances+in+the+genetics+of+glioblastoma%3A+are+we+reaching+critical+mass%5BTitle%5D)+AND+%22Nat.+Rev.+Neurol%22%5BJournal%5D)">Advances in the genetics of glioblastoma: are we reaching critical mass.</a> Nat. Rev. Neurol. 5, 419-426 (2009).</li>
</ol>

We have nothing to disclose.

Malignant gliomas, such as glioblastoma multiforme, represent the most common primary brain tumors and have a dismal prognosis4. Survival of patients affected by GBM has remained virtually unchanged during the last decade (i.e., 9-12 months post-diagnosis) despite advances in surgery, radiation, and chemotherapy5. The features of an appropriate model for the study of glioma treatment should include a reproducible tumor location and growth of the cells as a relatively discrete tumor; the cells should...

combination radiotherapy in an orthotopic mouse brain tumor model

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Glioblastoma multiforme (GBM) are the most common and aggressive adult primary brain tumors1. In recent years there has been substantial progress in the understanding of the mechanics of tumor invasion, and direct intracerebral inoculation of tumor provides the opportunity of observing the invasive process in a physiologically appropriate environment2. As far as human brain tumors are concerned, the orthotopic models currently available are established either by stereotaxic injection of cell suspensions or implantation of a solid piece of tumor through a complicated craniotomy procedure3. In our technique we harvest cells from tissue culture to create a cell suspension used to implant directly into the brain. The duration of the surgery is approximately 30 minutes, and as the mouse needs to be in a constant surgical plane, an injectable anesthetic is used. The mouse is placed in a stereotaxic jig made by Stoetling (figure 1). After the surgical area is cleaned and prepared, an incision is made; and the bregma is located to determine the location of the craniotomy. The location of the craniotomy is 2 mm to the right and 1 mm rostral to the bregma. The depth is 3 mm from the surface of the skull, and cells are injected at a rate of 2 &mu;l every 2 minutes. The skin is sutured with 5-0 PDS, and the mouse is allowed to wake up on a heating pad. From our experience, depending on the cell line, treatment can take place from 7-10 days after surgery. Drug delivery is dependent on the drug composition. For radiation treatment the mice are anesthetized, and put into a custom made jig. Lead covers the mouse's body and exposes only the brain of the mouse. The study of tumorigenesis and the evaluation of new therapies for GBM require accurate and reproducible brain tumor animal models. Thus we use this orthotopic brain model to study the interaction of the microenvironment of the brain and the tumor, to test the effectiveness of different therapeutic agents with and without radiation.

The purpose of this article is to describe the use of an orthotopic glioblastoma model for chemoradiation studies. This article will go though cell processing, implanting, and radiotherapy of the mouse using an intracranial model.

Glioblastoma multiforme (GBM) are the most common and aggressive adult primary brain tumors1. In recent years there has been substantial progress in the ...

The overall goal of this procedure is to describe, show and treat glioblastoma cells implanted intracranial in a mouse brain. This is accomplished by first preparing the cells and then implanting the cells into a mouse brain. After the surgical procedure, a tumor grows in the brain that can be experimented upon with various treatments.Ultimately, a survival curve can show whether or not the treatment was effective. The implications of this technique extend towards therapy of glioblastoma because it may be a more effective way of testing new treatments such as drugs and radiation versus in tissue culture Begin by growing the cells of interest such as U 87 cells to 80%confluence. In DMEM with 10%FBS one, two hundred and twenty five cubic centimeter flask will provide enough cells to implant five mice, aspirate the media off of the cells, and briefly wash the cells and 10 milliliters of PBS without calcium or magnesium with manual rocking.After aspirating the wash solution, trypsin eyes the cells after 10 to 15 minutes, neutralize the trypsin with 15 milliliters of media. Now transfer all cells and media into a 50 milliliter conical tube. Two flasks of cells will fit into one tube.Spin the cells down at 1600 RPM for seven minutes and completely remove the supernatant by aspiration. Resuspend the pellet in 10 milliliters of cold PBS, and rinse the cells by gently pipetting them up and down in solution until they make a uniform cloudy suspension. After measuring the cell concentration using a culture counter, repeat the PBS wash for optimal tumor growth.Adjust the final concentration of the U 87 cells to 200, 000 cells per microliter. Other cell lines may require a different concentration for optimal tumor growth. With the cells prepared for injection, keep them on ice and proceed with preparing the animal.Begin preparing the mice by delivering anesthetic to the host mice. After about 15 minutes, check that the mice are insensitive to pain with a toe pinch. Once anesthetized, apply an ointment to the eyes to prevent them from drying out.Then place the mouse on the bed for the stereotaxic frame. Hook the teeth in the notch of the mouth bar. Then position the bed in the frame.Now to steady the head, fit the mouse with a nose guard, and then gently insert the ear bars into the ear. Canals do not make either of these bars too tight as the skull can be fractured or the mouse could be suffocated. At this point, check that the head is level.The final preparation is to alternately swab the head with alcohol and iodine three times each and finish with a fourth application of alcohol. Start the implantation surgery with an incision beginning behind the right eye and going diagonally back to the left posterior of the skull. The incision should be about 10 to 15 millimeters long.Use a cotton applicator to slowly separate the incision, exposing the skull, wipe away the membrane that is between the skull and the skin, and blot any blood or excessive bleeding. Now, visualize the bgma and position a 10 microliter glass Hamilton syringe over it using a felt tip marker. Make a mark two millimeters right and one millimeter anterior of the bgma close to the anterior suture line.Now remove the syringe and drill a small hole in the skull at the marked position. The drill bit is the size of a 22 gauge needle. Let the bit do the boring into the skull.No additional pressure is needed. Using a 30 to 33 gauge needle syringe, load the syringe with five microliters of well mixed cells, and then reattach it to the frame. Line the needle up with the hole in the skull and lower it to the skull surface from the skull surface.Lower the needle three millimeters and wait two minutes. This pause reduces the chance of trauma. Slowly depress the plunger to implant the cells at a rate of about one microliter per minute.Carefully avoid any backflow after the last of the cells are implanted. Leave the needle in place for another two minutes to allow all the cells to settle in. After the weight, gently withdraw the needle from the brain and carefully wipe the hole clean with a cotton applicator.Now using five oh PBS suture, close the incision with about three stitches. Place the mouse on a heat pad and if needed, reapply. Eye ointment.Once the mouse lifts its head or moves its shoulders, return it to its home cage. From the time of the anesthesia injection, this procedure takes between 30 and 60 minutes. If the mouse has not stirred after 90 minutes, the mouse may not recover and euthanasia may be an effective alternative.Also, if there is excessive bleeding or the skull becomes cracked at any point during the procedure, euthanasia is advised. Depending on the cell line, radiation treatment of the mice can take place five to seven days post-implant. For example, an ortho voltage radiotherapy unit can be used for radiation treatment.Use imaging techniques such as B-L-I-M-R-I or CT to visualize the tumor prior to randomizing the mice into experimental groups. After the cell implantation, tumors typically formed within two to four weeks, depending on the cell line. Upon mortality, he staining was performed on the brain tissues to examine the tumor.An important evaluation of treatment efficacy is plotting a Kaplan-Meier survival curve. This compares the mean lifespan post-injection of animals that underwent drug treatment, radiation treatment, or a combined therapy. After this development, this technique has pave the way for research in the field of oncology to explore therapies of brain tumors and mice.

combination-radiotherapy-in-an-orthotopic-mouse-brain-tumor-model

Research

JoVE Journal

Medicine

Brain tumor patients routinely undergo cranial radiotherapy, and while beneficial, this treatment often results in debilitating cognitive dysfunction.  This serious unresolved problem has at present, no clinical recourse, and has driven our efforts to devise stem cell based therapies for the recovery of radiation-induced cognitive decrements.

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

The video demonstrates the breast cancer orthotopic inoculation technique in a mouse model. This technique produces a high tumorigenesis rate with less variability in tumor size and shape compared to subcutaneous or non-surgical injection.

Orthotopic Injection: Implanting Tissue Specific Cancer Cells into an Adult Mouse

This video demonstrates implantation of tumor cells in the mouse brain by performing intracranial injection.

Intracranial Orthotopic Model: A Procedure to Implant Cancer Cells in Mouse Brain

Stem cells are promising therapeutic carriers to treat brain tumors due to their intrinsic tumor tropism. Non-invasive intranasal stem cell delivery bypasses the blood brain barrier and demonstrates strong potential for clinical translation. This article summarizes the basic principles of intranasal stem cell delivery in a mouse model of glioma.

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

In the past, small animal irradiation was usually performed without the ability to target a well-delineated tumor volume. The goal was to mimic the treatment of human glioblastoma in rats. Using a small animal irradiation platform, we performed MRI-guided 3D conformal irradiation with PET-based sub-volume boosting in a preclinical setting.

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Here, we present a protocol for the preparation and the stereotaxic administration of allogeneic human lymphocytes in immunodeficient mice carrying orthotopic human primary brain tumors. This study provides a proof-of-concept for both the feasibility and the antitumor efficacy of intrabrain-delivered cellular immunotherapies.

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Research on treatment strategies for pluripotent stem cell-derived teratomas is important for the clinical translation of stem cell therapy. Here, we describe a protocol to, first, generate stem cell-derived teratomas in mice and, then, to selectively target and treat these tumors in vivo using a small-animal irradiator.

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Intracranial brain metastasis modeling is complicated by an inability to monitor tumor size and response to treatment with precise and timely methods. The presented methodology couples intracranial tumor injection with magnetic resonance imaging analysis, which when combined, cultivates precise and consistent injections, enhanced animal monitoring, and accurate tumor volume measurements.

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Here we present a protocol to perform preclinical positron emission tomography-based radiotherapy in a rat glioblastoma model using algorithms developed in-house to optimize the accuracy and efficiency.

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Here, we describe a preclinical orthotopic mouse model for GBM, established by intracranial injection of cells derived from genetically engineered mouse model tumors. This model displays the disease hallmarks of human GBM. For translational studies, the mouse brain tumor is tracked by in vivo MRI and histopathology.

Translational Orthotopic Models of Glioblastoma Multiforme

The development of orthotopic pediatric brain tumor models requires meticulous precision, using a stereotaxic device to implant cancer cells precisely. The methodology presented here outlines the steps involved in preparing brain tumor cells, performing intracranial injections, and implementing a post-operative monitoring system to assess brain tumor engraftment.

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Learn how to establish an orthotopic glioblastoma model in mice for chemoradiation studies. This method enables researchers to implant tumor cells, monitor growth, and evaluate treatment efficacy using survival curves.

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Explore More Videos